| dc.contributor.author | Hagh, MF | |
| dc.contributor.author | Fard, AD | |
| dc.contributor.author | Saki, N | |
| dc.contributor.author | Shahjahani, M | |
| dc.contributor.author | Kaviani, S | |
| dc.date.accessioned | 2018-08-26T09:31:09Z | |
| dc.date.available | 2018-08-26T09:31:09Z | |
| dc.date.issued | 2011 | |
| dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/56919 | |
| dc.description.abstract | Hemoglobin F (HbF, ? 2? 2) is a major contributor to the clinical heterogeneity and ameliorating agent observed in patients with the ?-globin disorders including ?-thalassemia and sickle cell disease (SCD). During fetal life, HbF is the major hemoglobin but is largely substituted by adult hemoglobin (HbA, ? 2? 2) following a globin expression switch after birth. Increased ?-globin expression can reduce the clinical severity of ?-thalassemia and SCD. Therefore, increase in HbF production has served as a longstanding goal. The progression of target-based therapeutics has been confused by limited comprehension of molecular mechanisms of gamma-globin gene expression. However, recent discoveries of regulators of HbF level represent a major development and provide new opportunities in employing novel rational therapeutic strategies. In this review, molecular mechanisms of hemoglobin F induction will be discussed. | |
| dc.language.iso | English | |
| dc.relation.ispartof | International Journal of Hematology-Oncology and Stem Cell Research | |
| dc.subject | 5 aza 2' deoxycytidine | |
| dc.subject | azacitidine | |
| dc.subject | beta globin | |
| dc.subject | butyric acid | |
| dc.subject | gamma globin | |
| dc.subject | hemoglobin F | |
| dc.subject | hydroxyurea | |
| dc.subject | lenalidomide | |
| dc.subject | pomalidomide | |
| dc.subject | protein Myb | |
| dc.subject | reactive oxygen metabolite | |
| dc.subject | thalidomide | |
| dc.subject | BCL11A gene | |
| dc.subject | beta globin gene | |
| dc.subject | disease severity | |
| dc.subject | down regulation | |
| dc.subject | drug effect | |
| dc.subject | drug mechanism | |
| dc.subject | drug potentiation | |
| dc.subject | gamma globin gene | |
| dc.subject | gene | |
| dc.subject | genetic association | |
| dc.subject | genetic polymorphism | |
| dc.subject | genetic variability | |
| dc.subject | HBG2 gene | |
| dc.subject | HBS1L gene | |
| dc.subject | human | |
| dc.subject | molecular dynamics | |
| dc.subject | molecular pathology | |
| dc.subject | MYB gene | |
| dc.subject | protein expression | |
| dc.subject | protein function | |
| dc.subject | protein induction | |
| dc.subject | quantitative trait locus | |
| dc.subject | review | |
| dc.subject | sickle cell anemia | |
| dc.subject | sickle cell beta thalassemia | |
| dc.subject | upregulation | |
| dc.title | Molecular mechanisms of hemoglobin F induction | |
| dc.type | Article | |
| dc.citation.volume | 5 | |
| dc.citation.issue | 4 | |
| dc.citation.spage | 5 | |
| dc.citation.epage | 9 | |
| dc.citation.index | Scopus | |
